Sinovac, whose CoronaVac is in Phase 3 clinical trials and has been included in the emergency scheme, offered the candidate vaccine to approximately 2,000 to 3,000 employees and their families on a voluntary basis, CEO Yin Weidong told Reuters."As a vaccine developer and manufacturer, a new outbreak could directly impact our vaccine production", Yin said on the sidelines of an worldwide trade fair in Beijing, explaining why his company was included in the emergency programme. Though yet to hit the market but the makers of the vaccine believe it will be approved after all-important phase 3 trials as early as year-end.
Australia's largest pharmaceutical company, said it had signed initial deals for the supply of vaccines against the novel coronavirus if they successfully complete clinical trials.
Earlier, Russia had said that it is planning to produce 6 million doses of coronavirus vaccine per month.
CSL CEO and Managing Director Paul Perreault said, "The social and economic impact of the COVID-19 pandemic has brought a high level of urgency to the task of developing a vaccine against the SARS-CoV-2 virus, and to manufacture a successful vaccine at high quality and in sufficient quantities. The preliminary results of the Phase 3 trial will be published in October-November 2020", said Dmitriev.
Johnson & Johnson’s Covid-19 vaccine shows promise in hamsters
Curevac is likely to be beaten to market by US rival Moderna and Germany's Biontech, billionaire backer Dietmar Hopp said earlier. UQ has recently announced that pre-clinical testing showed the vaccine is promising and already effective in animal models.
The Embassy of the Russian Federation in the Philippines told Congress that the Russian government is open to the proposal to set up a local manufacturing facility in the Philippines for the Covid-19 vaccine, "Sputnik V".
Hong Kong authorities indicated this weekend that they have placed a deposit for vaccines developed by Oxford University on August 31 through the World Health Organization, which looks to support the worldwide development and equitable distribution of a possible vaccine. The vaccines are being developed by Sinovac Biotech and Sinopharm, both Chinese companies.
Vaccine development programmes are now under way in most developed countries, including in China, Germany, Russia, the United Kingdom and the USA, each of which are considered to have candidates that are in the vanguard of attempts to find a successful vaccine as speedily as possible. Covaxin is one of the frontrunners in the race for a Covid-19 vaccine in India. India is one of the leading countries in production.
The study noted that the vaccine is "highly immunogenic".